LENZ Stock Analysis: LENZ Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 182m USD | 12M Return: -81.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.12M
Warnings
Tailwinds
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
LENZ Therapeutics, Inc. is a US-based commercial pharmaceutical company headquartered in Solana Beach, California, focused on developing and commercializing therapies to improve vision. Its lead product candidates, VIZZ and LNZ101, target presbyopia, an age-related loss of near-vision typically affecting adults over 40. The company was founded in 2013 and previously operated as Presbyopia Therapies, Inc. before adopting its current name in June 2021.
The company trades on NASDAQ under the ticker LENZ, having completed its IPO on June 25, 2021. It is classified within the Health Care sector and the Biotechnology sub-industry, a segment that typically relies on clinical trial outcomes and regulatory approvals to drive long-term value. With a micro-cap market capitalization of approximately $199M USD, LENZ represents a smaller, development-stage-oriented player in the ophthalmology pharmaceuticals space.
- VIZZ FDA approval enables U.S. commercial launch
- Cash burn may force dilutive equity raise
- Vuity competition and pipeline entrants challenge market share
| Net Income: -109.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -6.20 > 1.0 |
| NWC/Revenue: 1.16k% < 20% (prev 287k%; Δ -286k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -86.7m > Net Income -109.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.40 > 1.5 & < 3 |
| Outstanding Shares: last quarter (31.4m) vs 12m ago 13.90% < -2% |
| Gross Margin: 91.16% > 18% (prev -46.97%; Δ 138.1% > 0.5%) |
| Asset Turnover: 8.86% > 50% (prev 0.03%; Δ 8.83% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 268.4m - Total Current Liabilities 25.8m) / Total Assets 272.5m |
| B: -0.99 (Retained Earnings -268.6m / Total Assets 272.5m) |
| C: -0.46 (EBIT TTM -108.5m / Avg Total Assets 236.9m) |
| D: 9.46 (Book Value of Equity 246.5m / Total Liabilities 26.0m) |
| Altman-Z'' = 9.49 = AAA |
As of July 08, 2026, the stock is trading at USD 5.90 with a total of 1,332,926 shares traded. Over the past week, the price has changed by +2.43%, over one month by -12.20%, over three months by -39.24% and over the past year by -81.26%.
Current recommended Stop Loss: 5.30 (which is 10.2% or 1.3 ATR below the current price).
LENZ Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy LENZ.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 32 | 442.4% |
P/S = 8.6494
P/B = 0.7365
Revenue TTM = 21.0m USD
EBIT TTM = -108.5m USD
EBITDA TTM = -108.1m USD
Long Term Debt = 237k USD (estimated: total debt 673k - short term 436k)
Short Term Debt = 436k USD (from shortTermDebt, last quarter)
Debt = 673k USD (from shortLongTermDebtTotal, last quarter) (leases 673k already included)
Net Debt = -257.7m USD (calculated: Debt 673k - CCE 258.4m)
Enterprise Value = 181.5m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -108.5m / Interest Expense TTM 0.0)
EV/FCF = -2.08x (Enterprise Value 181.5m / FCF TTM -87.4m)
FCF Yield = -48.16% (FCF TTM -87.4m / Enterprise Value 181.5m)
FCF Margin = -416.6% (FCF TTM -87.4m / Revenue TTM 21.0m)
Net Margin = -519.3% (Net Income TTM -109.0m / Revenue TTM 21.0m)
Gross Margin = 91.16% ((Revenue TTM 21.0m - Cost of Revenue TTM 1.86m) / Revenue TTM)
Gross Margin QoQ = 37.56% (prev 66.94%)
Tobins Q-Ratio = 0.67 (Enterprise Value 181.5m / Total Assets 272.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 673k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -85.7m (EBIT -108.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.40 (Total Current Assets 268.4m / Total Current Liabilities 25.8m)
Debt / Equity = 0.00 (Debt 673k / totalStockholderEquity, last quarter 246.5m)
Debt / EBITDA = 2.38 (negative EBITDA) (Net Debt -257.7m / EBITDA -108.1m)
Debt / FCF = 2.95 (negative FCF - burning cash) (Net Debt -257.7m / FCF TTM -87.4m)
Total Stockholder Equity = 232.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.01% (Net Income -109.0m / Total Assets 272.5m)
RoE = -46.82% (Net Income TTM -109.0m / Total Stockholder Equity 232.8m)
RoCE = -46.56% (EBIT -108.5m / Capital Employed (Equity 232.8m + L.T.Debt 237k))
RoIC = -34.83% (negative operating profit) (NOPAT -85.7m / Invested Capital 246.1m)
WACC = 11.49% (E(181.5m)/V(182.2m) * Re(11.53%) + D(673k)/V(182.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 80.65%
[DCF] Fair Price = unknown (Cash Flow -87.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.26 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.05 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.07 | Chg30d=+0.00% | Revisions=-38% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-1.02 | Chg30d=+0.00% | Revisions=+0% | Analysts=7
EPS current Year (2026-12-31): EPS=-4.56 | Chg30d=+0.00% | Revisions=-67% | GrowthEPS=-60.0% | GrowthRev=-0.3%
EPS next Year (2027-12-31): EPS=-3.47 | Chg30d=+0.00% | Revisions=-38% | GrowthEPS=+23.9% | GrowthRev=+239.0%
[Analyst] Revisions Ratio: -48% (up=5, down=17)